Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 InfectionJin Yong Kim, Kim Ys, Jae‐Hyeong Park et al.|Clinical Therapeutics|2021Cited by 47
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019Joong Sik Eom, Oana Săndulescu, Liliana Preoțescu et al.|Open Forum Infectious Diseases|2022Cited by 42
Functional polysaccharides from <i>Grifola frondosa</i> aqueous extract inhibit atopic dermatitis-like skin lesions in NC/Nga miceGon Sup Kim, Yong Hyeon Hwang, Mun Ki Kim et al.|Bioscience Biotechnology and Biochemistry|2014Cited by 28